Strong launch execution driving company growth

As I reflect on the past year and UCB’s 2024 financial and extra financial performance, I am more certain than ever that our guiding principle - "Inspired by patients, driven by science" - has never been more relevant. In 2024, we focused on meaningful impact: breakthrough innovation and execution excellence to deliver transformative value to people living with severe diseases.

Twelve months ago, we set ambitious goals to launch new solutions that make a real difference. Today, I am proud to see those efforts come to life. We deliver on our commitments, and the results speak for themselves.

Our 2024 revenue increased by 17% to €6.15 billion, thanks to net sales of €5.61 billion driven by triple and double-digit performance of our growth medicine drivers. Underlying profitability rose by 9% to €1.48 billion and our profit more than tripled. Looking ahead we continue to have strong ambitions. We aim to obtain revenues in 2025 in the range of € 6.5 – €6.7 billion and an adjusted EBITDA to reach 30% of revenues, representing a significant increase over 2024 considering the evolution of our medicine portfolio. Since 2014, our revenue has increased by around 80%, adjusted EBITDA by more than 130%, and our market capitalization has tripled.

Our 2024 results go beyond our financial performance. Sustainability continues to be central to everything we do. Scientific progress must be responsible, and our growth should not come at the expense of our environment. I am proud that our net-zero climate targets have been validated by the Science-Based Targets initiative, holding us accountable for reducing our carbon footprint. Our ESG performance assessed by organizations such as Sustainalytics, ISS ESG, MSCI and CDP has placed us among industry leaders, reaffirming our responsibility to future generations.

Beyond reducing emissions, we are committed to equitable healthcare access. This year, we expanded our reach by 14% to reach 82% access coverage for our medicines, ensuring that more people - regardless of location or socioeconomic status - can access life-changing treatments.

With a strong foundation in innovation, ongoing launches of our key medicines, financial stability, and positive societal impact, I am confident about the road ahead. 2025 will bring continued momentum, driven by strong execution, sustained growth, and breakthrough innovation that delivers meaningful impact.

To my team members, partners, and stakeholders - thank you for being part of this journey. Your dedication makes this possible. Together, we will continue to transform the lives of people living with severe diseases and shape the future of healthcare in a responsible and impactful way.